Abstract: The invention provides compositions and methods of treating autism. Specifically, the invention relates to treating the core symptoms of autism by administering ?-methyl-DL-tyrosine.

Abstract: The present invention provides methods, compositions, and kits for treating retinopathy, including diabetic retinopathy and macular degeneration, in a subject in need.

Abstract: The invention provides compositions and methods of treating autism. Specifically, the invention relates to treating the core symptoms of autism by administering alpha-methyl-DL-tyrosine.

Abstract: The present invention provides methods, compositions, and kits for treating anxiety-related disorders, including OCD and SAD, and for reducing anxiety, obsessive behavior, or compulsive behavior in subjects in need thereof.

Abstract: The present inventions provide compositions and methods for modulating tumors in non-human mammals using a tyrosine derivative.

Abstract: The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (IBD), graft versus host disease (GVHD), HIV/AIDS, multiple organ dysfunction syndrome, irritable bowel syndrome (IBS), celiac disease, eczema, psoriasis, acute pancreatitis, Parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.

Abstract: The invention provides compositions and methods of treating autism. Specifically, the invention relates to treating the core symptoms of autism by administering ?-methyl-DL-tyrosine.

Abstract: The disclosure is directed to methods of using hydrophilic bile acids for the treatment of viral infections.

Abstract: The present disclosure is directed to methods of treating conditions characterized by insulin deficiency in animals by trans dermal insulin administration.

Abstract: The present disclosure is directed to methods, compositions, and kits for treating amyotrophic lateral sclerosis.

Abstract: The invention provides compositions and methods of treating autism. Specifically, the invention relates to treating the core symptoms of autism by administering ?-methyl-DL-tyrosine.

Abstract: The disclosure is directed to methods of using TUDCA, or a pharmaceutically acceptable salt thereof, or a derivative thereof, for the treatment of SARS-CoV-2 infections.

Abstract: The present invention provides methods, compositions, and kits for treating anxiety-related disorders, including OCD and SAD, and for reducing anxiety, obsessive behavior, or compulsive behavior in subjects in need thereof.

Abstract: Disclosed are methods for treating cancer by reduction of glycogen stores and administering tyrosine derivatives.

Abstract: Compositions and kits comprising a tyrosine hydroxylase inhibitor and an anticancer agent that is chemically bonded to, or physically associated with, the tyrosine hydroxylase inhibitor are provided. Also provided are methods for reducing cell proliferation in a subject comprising administering to a subject in need thereof a composition comprising a tyrosine hydroxylase inhibitor and an anticancer agent that is chemically bonded to, or physically associated with, the tyrosine hydroxylase inhibitor.

Abstract: The present invention provides methods, compositions, and kits for treating anxiety-related disorders, including OCD and SAD, and for reducing anxiety, obsessive behavior, or compulsive behavior in subjects in need thereof.

Abstract: The present invention provides methods, compositions, and kits for treating retinopathy, including diabetic retinopathy and macular degeneration, in a subject in need.

Abstract: The invention relates to tyrosine hydroxylase inhibitor compositions and methods of preparing and administering thereof. Specifically, the invention relates to an oral chewable formulation of a tyrosine hydroxylase inhibitor, particularly ?-methyl-DL-tyrosine.

Abstract: The present disclosure is directed to percutaneous compositions containing an antiseptic, an antibiotic, an antifungal agent, an antihelminth agent, an antiviral agent, or an NSAID.

Abstract: The invention relates to tyrosine hydroxylase inhibitor compositions and methods thereof. Specifically, the invention relates to a sustained release formulation of a tyrosine hydroxylase inhibitor, particularly ?-methyl-para-tyrosine.